Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

International Journal of Cardiology

Volumn 154, Issue 3, 2012, Pages 341-344

  Stefanadis, Christodoulos ^a   Synetos, Andreas ^a   Tousoulis, Dimitris ^a   Tsiamis, Eleftherios ^a   Michelongona, Archontoula ^a   Zagouri, Flora ^c   Bamias, Aristotle ^c   Dimopoulos, Meletios Athanasios ^c   Kyvelou, Stella ^b   Kapelakis, Ioannis ^d   Toutouzas, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Bevacizumab; Neovascularization; Systolic dysfunction; Vasa vasorum

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; PACLITAXEL;

ADULT; ATHEROSCLEROSIS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLORECTAL CANCER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG FATALITY; ECHOCARDIOGRAPHY; FEMALE; GREECE; HEART INFARCTION; HEART VENTRICLE SEPTUM; HEART VENTRICLE SIZE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ONCOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SIDE EFFECT; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN DEATH; TREATMENT DURATION;

EID: 84855942935     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.115     Document Type: Article

References (8)

1. T. Shuin, K. Kondo, and S. Torigoe Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 54 1994 2852 2855
2. S.R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
3. C. Stefanadis, K. Toutouzas, E. Stefanadi, A. Lazaris, E. Patsouris, and N. Kipshidze Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study Atherosclerosis 195 2007 269 276 (Pubitemid 350087955)
4. K. Toutouzas, J. Karabelas, S. Vaina, and C. Stefanadis Antivascular endothelial growth factor-a treatment: new perspectives for high-risk plaque stabilization J Am Coll Cardiol 50 2007 186 (Pubitemid 47002184)
5. A. Bamias, and M.A. Dimopoulos Inhibition of angiogenesis: common theme for cancer and atheromatosis? Hellenic J Cardiol 47 2006 11 12
6. C. Stefanadis, K. Toutouzas, E. Stefanadi, F. Kolodgie, R. Virmani, and N. Kipshidze First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model Hellenic J Cardiol 47 2006 7 10
7. C. Stefanadis, K. Toutouzas, E. Stefanadi, E. Tsiamis, M. Vavuranakis, and N. Kipshidze Avastin-eluting stent: long-term angiographic and clinical follow up Hellenic J Cardiol 49 2008 188 190 (Pubitemid 351792648)
8. C. Stefanadis, K. Toutouzas, E. Tsiamis, M. Vavuranakis, E. Stefanadi, and N. Kipshidze First-in-man study with bevacizumab-eluting stent: a new approach for the inhibition of atheromatic plaque neovascularisation EuroIntervention 3 2008 460 464